Fermenta Biotech's 73rd AGM presentation highlights a robust FY25 financial turnaround.

Consolidated revenue surged 39% to ₹481 Cr, marking a significant recovery from prior year losses, with EBITDA at ₹122 Cr and net profit at ₹76 Cr.

The company's strategic realignment, focusing on execution and innovation, delivered these results.

Key initiatives include expanding plant-source Vitamin D3, Spray-Dried Vitamin D3, and Vitamin K1 portfolios.

With a strengthened balance sheet and diversified global revenue streams, Fermenta is positioned for sustained growth in nutritional wellness, aiming for continued momentum.